122 related articles for article (PubMed ID: 26219108)
1. [Rapidly Growing Interval Colon Cancer].
Kim JH; Park MI
Korean J Gastroenterol; 2015 May; 65(5):326-9. PubMed ID: 26219108
[No Abstract] [Full Text] [Related]
2. [A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].
Kume S; Takahashi M; Kubota T; Hirata T; Torigoe Y; Ikeda O; Goto Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1809-12. PubMed ID: 20841953
[TBL] [Abstract][Full Text] [Related]
3. Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.
Abu-Ghanem S; Novik EF; Abu-Ghanem Y; Man S; Shelef I
Isr Med Assoc J; 2011 Oct; 13(10):638-9. PubMed ID: 22097237
[No Abstract] [Full Text] [Related]
4. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Duran AO; Karaca H; Besiroglu M; Bayoglu IV; Menekse S; Yapici HS; Yazilitas D; Bahceci A; Uysal M; Sevinc A; Hacibekiroglu I; Aksoy A; Tanriverdi O; Arpaci E; Inanc M; Dane F; Ozkan M
Asian Pac J Cancer Prev; 2014; 15(23):10375-9. PubMed ID: 25556478
[TBL] [Abstract][Full Text] [Related]
5. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
de Melo JV; Vieira de Melo MS; Abad MH
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
[TBL] [Abstract][Full Text] [Related]
6. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Van Loon K; Venook AP
J Clin Oncol; 2014 Apr; 32(10):991-6. PubMed ID: 24516031
[No Abstract] [Full Text] [Related]
7. [A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
Sugimoto K; Tashiro Y; Nagayasu K; Niwa K; Ono S; Ishiyama S; Hata M; Komiyama H; Takahashi M; Yaginuma Y; Kojima Y; Goto M; Tanaka M; Sengoku H; Okuzawa A; Tomiki Y; Sakamoto K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1167-70. PubMed ID: 20567130
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-associated reversible hypotension.
Iqbal K; Chu Q; Mei Q; Chen Y
Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):800-1. PubMed ID: 17825542
[No Abstract] [Full Text] [Related]
10. Sequential or combination chemotherapy for a patient with mCRC?
Arnold D
Cancer Treat Rev; 2008; 34 Suppl 2():S12-6. PubMed ID: 19101403
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of colorectal cancer.
Marshall JL
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585
[No Abstract] [Full Text] [Related]
12. Metastatic polyps in the hepatic flexura of the colon.
Köklü S; Koçak E; Tas A; Biyikoğlu I; Ustün H
Clin J Oncol Nurs; 2010 Dec; 14(6):683-4. PubMed ID: 21112845
[No Abstract] [Full Text] [Related]
13. [A case of unresectable multiple hepatic metastases from ascending colon cancer successfully treated with panitumumab and FOLFIRI(5-FU/LV/irinotecan)therapy].
Yoshida R; Matsuura T; Hijikawa K; Yanagida H; Kitade H; Takada H; Kwon AH
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1575-7. PubMed ID: 23064076
[TBL] [Abstract][Full Text] [Related]
14. [A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6].
Tanaka K; Toyokawa A; Kanemitsu K; Okuda T; Iwasaki T; Ishida T
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1117-20. PubMed ID: 20567119
[TBL] [Abstract][Full Text] [Related]
15. [A case of undifferentiated colon cancer responding to FOLFIRI therapy].
Fujiwara K; Nagayoshi Y; Nakahara C; Yamasaki T; Iwashita T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1525-7. PubMed ID: 21918355
[TBL] [Abstract][Full Text] [Related]
16. Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Maleux G; Vaninbroukx J; Heye S; van Cutsem E; Oyen R
Acta Oncol; 2010 Aug; 49(6):864-6. PubMed ID: 20230212
[No Abstract] [Full Text] [Related]
17. Colon cancer, version 3.2014.
Benson AB; Venook AP; Bekaii-Saab T; Chan E; Chen YJ; Cooper HS; Engstrom PF; Enzinger PC; Fenton MJ; Fuchs CS; Grem JL; Hunt S; Kamel A; Leong LA; Lin E; Messersmith W; Mulcahy MF; Murphy JD; Nurkin S; Rohren E; Ryan DP; Saltz L; Sharma S; Shibata D; Skibber JM; Sofocleous CT; Stoffel EM; Stotsky-Himelfarb E; Willett CG; Gregory KM; Freedman-Cass DA;
J Natl Compr Canc Netw; 2014 Jul; 12(7):1028-59. PubMed ID: 24994923
[TBL] [Abstract][Full Text] [Related]
18. The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.
Grothey E; Chu E
Clin Colorectal Cancer; 2007 Sep; 6(9):621-4. PubMed ID: 17945033
[No Abstract] [Full Text] [Related]
19. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
[No Abstract] [Full Text] [Related]
20. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Ocvirk J; Rebersek M; Boc M
Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
